Bridgebio Pharma, innovators working to create life-altering medicines, filed for an IPO with NASDAQ under the symbol “BBIO”.
Bridgebio Pharma offering 20.0 million shares at a price range of $14.00 – $16.00.
Manager and Joint Managers- J.P. Morgan, Goldman Sachs, Jefferies, SVB Leerink, KKR. Piper Jaffray, Mizuho Securities, BMO Capital Markets and Raymond James act as co-managers. The IPO is expected to price on June 27, 2019.
We are a team of experienced drug discoverers, developers and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source. We founded BridgeBio in 2015 to identify and advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Our pipeline of over 15 development programs includes product candidates ranging from early discovery to late-stage development.
The IPO is expected to trade on NASDAQ on June 27, 2019
Featured photo credit to internet